We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




Novel Cryopreservation Method Reduces Procedural Toxicity

By HospiMedica International staff writers
Posted on 08 Dec 2015
A new study describes how mathematical modeling could advance ice-free cryopreservation, i.e., vitrification, paving the way for optimized tissue and organ preservation.

Researchers at Oregon State University (OSU; Corvallis, USA) and Northern Illinois University (DeKalb, USA) designed a mathematical approach to identify and modify minimally toxic cryoprotective agent (CPA) equilibration procedures. More...
To do so, they first developed a concentration- and temperature-dependent toxicity cost function by exposing adherent endothelial cells to a range of glycerol concentrations at 21 °C and 37 °C, and fitting the resulting viability data to a first order cell death model.

The resulting toxicity cost function was then numerically minimized to establish a state-constrained optimization routine intended to minimize cell damage during the cryopreservation procedure, a routine which involves initially exposing the adherent endothelial cells to a low concentration of cryoprotectant, and then allowing time for the cells to swell. Following the swelling stage, the tissue sample can then be rapidly vitrified by adding a high concentration of CPA, resulting in much less overall toxicity.

The researchers then conducted lab tests using the predicted optimal procedure routine, and succeeded in obtaining 81% cell recovery after exposure to the vitrification solutions, as well as successful vitrification with relatively slow cooling and warming rates of 50 °C/min and 130 °C/min. In comparison, similar cell tissues that underwent conventional multistep CPA equilibration procedures resulted in much lower yields, of only about 10%. The study was published on November 35, 2015, in PLOS One.

“The biggest single problem and limiting factor in vitrification is cryoprotectant toxicity, and this helps to address that,” said associate professor Adam Higgins, PhD, of the OSU School of Chemical, Biological, and Environmental Engineering. “The model should also help us identify less toxic cryoprotectants, and ultimately open the door to vitrification of more complex tissues, and perhaps complete organs.”

“Many more applications of vitrification could be possible, especially as future progress is made in the rapidly advancing field of tissue regeneration, in which stem cells can be used to grow new tissues or even organs,” concluded Dr. Higgins. “Tissues could be made in small amounts and then stored until needed for transplantation; organs being used for transplants could be routinely preserved until a precise immunological match was found for their use. Conceptually, a person could even grow a spare heart or liver from their stem cells and preserve it through vitrification.”

Cryopreservation is a process in which cells, whole tissues, or any other substances susceptible to damage caused by chemical reactivity or time are preserved by cooling to sub-zero temperatures so as to stop enzymatic activity. By default it should be considered that cryopreservation alters or compromises the structure and function of cells, unless it is proven otherwise for a particular cell population.

Related Links:

Oregon State University
Northern Illinois University



Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Ultrasound Needle Guidance System
SonoSite L25
Silver Member
X-Ray QA Device
Accu-Gold+ Touch Pro
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.